Today: 21 May 2026
Browse Category

TSX:285A 26 November 2025 - 27 November 2025

Kioxia Holdings (285A) Stock Today, November 27, 2025: Price Rebound After Bain Selldown as US–Japan Chip Plant Hopes Emerge

Kioxia Holdings (285A) Stock Today, November 27, 2025: Price Rebound After Bain Selldown as US–Japan Chip Plant Hopes Emerge

Kioxia shares rose 5.63% to ¥8,858 in Tokyo on November 27 after plunging nearly 15% the previous day, following a 36 million-share secondary sale by Bain Capital–backed BCPE Pangea Cayman LP. The block trade, priced at a discount, raised an estimated ¥330–355 billion and increased Kioxia’s free float. Bain remains the largest shareholder but is reducing its stake. Trading volume reached about 15.96 million shares.
27 November 2025
·
Kioxia Holdings (285A.T) Stock Slumps on Bain’s $2 Billion Selldown – What Investors Need to Know Today, 26 November 2025

Kioxia Holdings (285A.T) Stock Slumps on Bain’s $2 Billion Selldown – What Investors Need to Know Today, 26 November 2025

Kioxia shares fell about 11% to ¥8,767 in Tokyo by 9:55 a.m. JST after Bain Capital moved to sell 36 million shares, worth roughly $2–2.3 billion, to overseas investors via a block trade. Trading volume surged past 10 million shares early, with the stock swinging between ¥8,505 and ¥8,859. Kioxia’s market cap stands near ¥5.3 trillion. The sale represents about 6.7% of outstanding shares.
26 November 2025
·

Stock Market Today

  • Stock Market Futures Fall on May 20, 2026, as Investors React to Nvidia Earnings
    May 20, 2026, 7:32 PM EDT. U.S. stock futures dropped Wednesday evening, reflecting investor caution after Nvidia ($NVDA) reported earnings. The AI chipmaker's results sparked debate over whether they met lofty expectations, influencing market sentiment ahead of Thursday's open. Futures contracts, which allow investors to buy or sell assets at a predetermined price for future delivery, indicated a tentative market tone. Traders are assessing Nvidia's outlook amid broader concerns about the tech sector's growth momentum and valuation pressures. This cautious stance highlights the sensitive market environment as investors balance strong earnings reports against economic headwinds and sector-specific risks.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop